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ABSTRACT
Rosacea is a common, chronic inflammatory
skin disease that can present with a variety of
signs and symptoms. The potentially
simultaneous occurrence of different signs and
symptoms is due to different underlying
inflammatory pathways, emphasizing the need
for complementary treatment approaches.
Topical ivermectin cream (10 mg/g) and
systemic, oral anti-inflammatory doxycycline
(40 mg modified-release) are both approved for
the treatment of papulopustular rosacea (PPR).
Whether or not a combined therapeutic
approach may be more beneficial than
monotherapy for patients with PPR remains to
be tested. Here, we summarize underlying
inflammatory pathways implicated in rosacea
and clarify the impact of these two agents on
selective pathways during inflammation, due to
specific characteristics of their individual
mechanisms of action (MoA). Based on the
complementary MoA of doxycycline
modified-release and ivermectin, a scientific
rationale for a combined therapy targeting
inflammatory lesions in rosacea is given. We
propose that topical ivermectin cream is a
promising new candidate as first-line
treatment to target the inflammatory lesions
of rosacea, which can be used in combination
with systemic doxycycline modified-release to
provide an optimal treatment approach
considering all inflammatory pathways
involved in PPR.
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INTRODUCTION
Rosacea is a chronic inflammatory disease
characterized by the presence of various signs
and symptoms including flushing (transient
erythema), persistent erythema, inflammatory
papules and pustules (inflammatory lesions),
telangiectasia, skin irritation (burning and
stinging), etc. These signs and symptoms can
occur in isolation or combination [1, 2].
Recommendations for the classification of
rosacea into four subtypes based on clinical
presentation were proposed in 2002, as follows:
erythematotelangiectatic rosacea (ETR);
papulopustular rosacea (PPR); phymatous
rosacea (PYR); and ocular rosacea (OR).
However, patients usually present with a
spectrum of symptoms overlapping these
subtypes [1, 2]. For example, although PPR is
characterized by the presence of lesions
(papules, pustules), patients may also
additionally present with persistent erythema
[2], and if the papules/pustules are cured, the
erythema still remains. Furthermore, PYR is
observed after or at the same time as PPR and
erythema (either transient or persistent) [3, 4].
Symptoms may vary from one week to the next,
making the disease unpredictable, which can
affect the patient’s quality of life [2, 5]. Finally,
scientific evidence indicates that the erythema
observed in ETR is an inflammatory process and
the underlying cause demands
anti-inflammatory therapy [6–10].
Signs and symptoms of rosacea often appear
to be triggered by environmental factors,
including sun exposure, temperature change,
stress, spicy foods, and heavy exercise [11, 12].
Recent epidemiological studies have indicated
that rosacea also has a genetic component
[6, 13]. Affected rosacea skin exhibits increased
sensitivity to these triggers [14]; for example,
compared with people with non-lesional skin,
individuals with PPR have a significantly lower
threshold for temperature-induced pain,
resulting in facial hypersensitivity [15]. This is
thought to be due to a hyper-responsive
immune system and increased levels of
proteins involved in inflammatory pathways
[14]. Neurovascular and neuro-immune
dysregulation may contribute to erythematous
changes (flushing, erythema) in rosacea
patients, which can impact innate and
adaptive immune defense mechanisms [6–9];
whether the autonomic or sensory nervous
system (or both) is crucial for the mediation of
flushing or erythema is still under debate
[16, 17]. A link has also been established
between the presence of high levels of
Demodex mites (such as D. folliculorum and D.
brevis) and rosacea, with signs and symptoms of
rosacea potentially resulting from heightened
pro-inflammatory skin response [18–24].
Whether the impact of Demodex mites is more
quantitative or qualitative, and whether or not
Demodex mites play a role in erythema as well as
in the development of papules/pustules, is still
under investigation.
Despite our current knowledge of trigger
factors and potential role of genetics, the
etiology of rosacea is yet to be fully elucidated
[12]. An important interplay exists between the
key mechanisms that are responsible for
underlying pathophysiology of the disease,
namely innate and adaptive immunity as well
as neurovascular dysregulation [4, 14, 25, 26].
These altered pathophysiological inflammatory
processes correlate well with the clinical signs/
symptoms of the disease. Although they are
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only partly understood, the correlation between
innate and adaptive immunity, in which the
infiltrate leads to the development of papules
and pustules, has been demonstrated. Because
the inflammatory infiltrate in PPR consists of
innate immune cells (papules: macrophages,
mast cells; pustules: neutrophils) and adaptive
immune cells (T helper [Th] 1 and Th17 cells, as
well as plasma cells) [6–10], a combination of
different drugs that optimally block the various
inflammatory pathways may be necessary. This
may also be true for the optimal treatment of
neurovascular dysregulation, namely flushing
(transient erythema) and persistent erythema,
for which the underlying mechanisms are still
poorly understood. For example, recent data
indicate that angiogenesis may not play an
important role in the context of erythema
[7, 10]. The glandular hyperplasia and fibrotic
changes, as observed in PYR, are now seen as a
result of chronic inflammatory stimuli,
although the pathophysiology of this
development on the molecular level is poorly
understood [12, 25, 26]. Overall, the various
inflammatory cells and pathways involved in
the pathophysiology of these overlapping yet
distinct signs of rosacea highlight the necessity
to implement optimized combination therapies
for greater benefit to the patient. This fact is also
supported by evidence in other dermatological
diseases such as acne or psoriasis, where
consensus guidelines recommend the use of a
combination of different therapies with
complementary mechanisms of action to
target multiple pathogenic factors
simultaneously [27, 28].
The aim of this review is to discuss the
complementary and distinct mechanisms of
action (MoA) of topical ivermectin 10 mg/g
cream and systemic doxycycline 40 mg
modified-release, which could be used in
combination to optimize efficacy in the
treatment of PPR. From this current evidence,
we propose that ivermectin 10 mg/g cream is a
promising new candidate as the first-line agent
in the treatment of the inflammatory lesions of
rosacea which, when used in combination with
doxycycline modified-release, could potentially
provide an even more effective, faster, and
longer-acting treatment approach. This article
is based on previously conducted studies and
does not involve any new studies of human or
animal subjects performed by any of the
authors.
POTENTIAL ROLE OF THE INNATE




Innate Immune System Response
The facial skin of people with rosacea-prone
skin expresses anomalous levels of certain
proteins with an ability to trigger
pro-inflammatory pathways and modulate
vascular changes (Fig. 1) [16, 29–34].
Histological examination of papulopustular
inflammatory lesions has demonstrated both
superficial and deep inflammation, consisting
of a mixed inflammatory infiltrate containing
macrophages, mast cells, Th1/Th17 cells and
eosinophils [8], as well as the presence of
Demodex mites [12]. Neutrophils are only
found in pustules and plasma cells are
occasionally present [7, 8, 12].
During the inflammatory process in rosacea,
chronic inflammation results in prolonged
vasodilation, allowing fluid to leak out. This,
in turn, causes edema, infiltration of leukocytes
and production of pro-inflammatory cytokines,
such as tumor necrosis factor alpha (TNF-a),
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interleukin (IL)-1, and IL-6, which eventually
leak into the dermis [35]. This vascular leakage
attracts additional neutrophils, which are
recruited by chemotactic factors released from
inflamed dermal structures [35]. Leukocytes
release nitric oxide (NO), matrix
metalloproteinases (MMPs), and reactive
oxygen species (ROS), which contribute to
chronic vasodilation and dermal matrix
degradation [35, 36]. Significantly elevated
levels of ROS are responsible for the initiation
of several pro-inflammatory processes in the
skin, including expression of
leukocyte-attracting chemokines, C–C motif
chemokine ligand 2 (CCL2), and C-X-C motif
chemokine 8 (CXCL8) [37]. During this process,
pro-inflammatory cytokines such as TNF-a and
IL-1 become upregulated, promoting leukocyte
chemotaxis [37]. In addition, the leakage of
pro-inflammatory cytokines such as TNF-a and
IL-1 into the dermis triggers production of
secondary chemokines (including CXCL1,
CXCL8, CCL20, and CCL27) in keratinocytes,
leading to T cell recruitment into the
perifollicular space, contributing to disease
progression [37].
Rosacea skin may be more sensitive to
specific triggers due to irregular expression of
certain proteins, such as toll-like receptor-2
(TLR2), serine protease kallikrein (KLK), and
Fig. 1 Innate immune dysfunction in rosacea. Overview
of innate immune-mediated inﬂammatory responses in
rosacea. UV light activates the vitamin D pathway, leading
to increased levels of cathelicidin. Activation of TLR2
leads to increased levels and activity of KLKs (e.g., KLK5),
resulting in increased cleavage of cathelicidin to form
LL-37, causing release of pro-inﬂammatory cytokines; mast
cell activation, and macrophage and neutrophil
chemotaxis. In response to trigger factors (e.g., stress,
spices, exercise, noxious cold, and heat), TRPV1 and/or
TRPA1 channels become activated, inducing neuropeptide
responses, which activate/amplify the inﬂammatory
response leading to the signs and symptoms of rosacea.
KLKs kallikreins, MMPs matrix metalloproteinases, TLR2
toll-like receptor 2, ROS reactive oxygen species, UV
ultraviolet. Modiﬁed from Yamasaki et al. [29, 30, 34],
Two et al. [31], Muto et al. [32], Reinholz et al. [33], and
Steinhoff et al. [16]
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abnormal forms of cathelicidin [2, 29].
Signaling via TLRs upregulates the vitamin D
receptor, causing induction of the cathelicidin
pathway [34, 38] and increased expression of
TLR2, which in turn induces a
calcium-dependent increase KLK5 levels in
keratinocytes and subsequent increase in
serine protease activity by KLK5 [29, 33]. KLK5
activity and post-translational processing
cleaves the C-terminal cathelin domain of the
inactive precursor of cathelicidin, hCAP18, to
give rise to the active peptide LL-37 [36].
Increased cathelicidin expression in rosacea
skin promotes leukocyte infiltration and
stimulates angiogenesis [30]. MMP cleavage/
activation of KLK5 indirectly catalyzes the
proteolytic activation of hCAP18 to LL-37;
therefore, MMP activation of KLK5 can
increase the levels of LL-37, leading to
increased inflammation [36]. Inhibition of
KLK5 has been linked with a reduction in the
occurrence of papules and erythema severity,
providing further evidence of this pathway in
the pathogenesis of rosacea [39]. This has
recently been demonstrated in a clinical
setting, with patients with PPR treated with
doxycycline 40 mg modified-release showing a
decrease in both gene expression and protein
levels of MMPs, KLK, and cathelicidin, which
resulted in a reduction in inflammatory lesion
count and consequently improved clinical
outcomes [40].
Mast cells have also been implicated in the
pathophysiology of rosacea, with the number of
mast cells shown to be elevated in the dermis of
rosacea patients presenting with different
subtypes [7, 32]. When mast cells in the skin
are activated, they secrete proteases such as
chymase, tryptase, KLK5, and MMPs, which
induce dermal inflammation and increase the
production of enzymes in the epidermal layer
that generate LL-37, thereby creating a
pro-inflammatory loop [32, 41]. In the skin,
mast cells are primarily found in the epidermis
and dermis in close proximity to keratinocytes
and sensory nerves endings; the secretion of
proteases, histamine, and pro-inflammatory
cytokines by mast cells contributes to the
amplification of the skin inflammation, tissue
remodeling, and angiogenesis [32].
Increased stratum corneum permeability has
been linked to an aggravated innate immune
response [26], with barrier impairment causing
skin sensitivity in patients with rosacea [42].
Elevated levels of serine proteases can
contribute to stratum corneum permeability
barrier dysfunction [14]. The innate immune
system may be activated as a homeostatic
counter-regulatory response to impaired
stratum corneum barrier, resulting in increased
trans-epidermal water loss (TEWL), and
increased expression and secretion of
cathelicidin (LL-37) [14]. Compared with
control subjects, patients with both PPR and
ETR have increased TEWL and heightened
reactivity to skin irritation using lactic acid
[43]. Individuals with PPR have also been found
to have reduced epidermal hydration and a
more alkaline centro-facial region compared
with controls [44].
Adaptive Immune System Response
The adaptive immune system has been shown
to contribute to inflammation in several
inflammatory dermatoses including acne [45],
psoriasis [46], atopic dermatitis [47], and
rosacea [8]. In a recent study, it was
demonstrated that expression of CD4? T cells
in the three facial subtypes (PPR, ETR, and PYR)
was significantly increased compared with
normal skin at all stages of rosacea; the
highest levels of CD4? cells, primarily
localized to the hair follicles, were recorded in
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patients with PPR [8]. In addition, of the three
subtypes investigated, individuals with PPR
demonstrated the highest gene expression
levels for T cell activation and
proliferation-associated genes (e.g., Lck, Vav1),
costimulatory molecules for T cell activation
(including Cd80, Cd86, and Tnfsf14) and
pro-inflammatory cytokines such as Il-1b [8].
Transcriptome analysis of induced T cell
response genes isolated from rosacea infiltrate
found that gene expression levels of the
Th1-signature cytokines interferon-gamma
(Ifn-c) and Tnf-a and Th1-immune
response-associated cellular receptors
(including Il12rb1 and Ccr5) were significantly
elevated in PPR, indicating a Th1-polarized
immune response in rosacea [8].
Elevated levels of antibody-producing B cells
can be found in patients with PPR or PYR [8];
however, the role of B cells in the pathogenesis
of rosacea has yet to be fully elucidated.
Evidence from other disease models indicate a
potential role of B cells in disease development,
with B cell activation having been shown to
contribute to downstream inflammatory
infiltration of other immune cells via TLR
signaling in a model of skin fibrosis [48]. In
addition, CD19 expression in B cells was found
to play a key role in antigen-specific CD4? T cell
proliferation and Th2 and Th17 responses in a




In patients with PPR, the aims of treatment are
to alleviate signs and symptoms such as
inflammatory lesions, lesional redness, and
subsequently the inflammatory background
erythema; to delay progression of disease; to
facilitate remission; and to avoid exacerbations
[50]. Before 2014, there were a limited number
of treatments indicated for use on the
inflammatory lesions of rosacea [51]: topical
azelaic acid gel (FINACEA 150 mg/g, Bayer
plc.) [52]; topical metronidazole gel, cream,
and lotion (METROGEL 7.5 mg/g and 10 mg/
g, METROCREAM 7.5 mg/g, and
METROLOTION 7.5 mg/mL, Galderma Ltd.)
[53]; and oral doxycycline 40 mg
modified-release (EFRACEA/ORACEA/
ORAYCEA, Galderma Ltd.) [54].
Ivermectin 10 mg/g (1%) cream
(SOOLANTRA, Galderma Ltd.) received Food
and Drug Administration (FDA) approval for the
treatment of the inflammatory lesions of
rosacea in December 2014 [55], and first
European approval in March 2015 [56].
Ivermectin has a similar structure to macrolide
antibiotics [57, 58]; however, its use is not
associated with the development of antibiotic
resistance [59, 60]. As a semi-synthetic
derivative of avermectin (macrocyclic lactones)
[57, 58], oral ivermectin has been used as an
anti-parasitic since the 1970 s [61–63], and is
associated with reduction of levels of mites,
such as Demodex mites, on the skin [55, 64].
In vitro and in vivo studies have also
demonstrated that oral ivermectin strongly
reduces the priming of specific effector T cells
(Ventre et al., submitted), and accumulation of
neutrophils and monocytes [65].
Oral ivermectin also acts further downstream
in inflammatory pathways, having previously
been shown to inhibit lipopolysaccharide
(LPS)-induced production of pro-inflammatory
cytokines, including TNF-a, IL-1, and IL-6 [66],
through the inhibition of the nuclear factor
kappa B (NF-jB) pathway [66]. Ivermectin is
able to suppress production of the
inflammatory mediators NO and prostaglandin
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E2 (PGE2), and reduce inducible NO synthase
(iNOS) and cyclooxygenase-2 (COX2) mRNA
expression levels by inhibiting phosphorylation
of the mitogen-activated protein kinases
(MAPK) p38, extracellular-signal-regulated
kinase (ERK) 1/2, and c-Jun N-terminal kinase
(JNK) [67]. NO can generate or modify
intracellular signals, thereby affecting the
function of immune cells [67]. The
modulation of NO, iNOS, COX2, and PGE2
release are major contributing factors during
the inflammatory process. Inhibition of NO and
PGE2 production by ivermectin results from the
inhibition of iNOS and COX2 gene expression
[67]. The MoA of ivermectin is yet to be fully
elucidated, but a proposed MoA has been
derived from the current preclinical evidence
(Fig. 2). Further studies will be needed to
confirm this proposed MoA.
Recently, the anti-inflammatory effects of
topical ivermectin have been demonstrated in
clinical trials, as shown by decreased counts of
inflammatory lesions [59, 68], although further
studies will be required to confirm the exact
anti-inflammatory effects of topical ivermectin
in PPR.
Phase III clinical trials have been conducted,
investigating the efficacy and safety of
ivermectin 10 mg/g cream in the treatment of
inflammatory lesions of rosacea. In two studies,
Stein Gold et al. [59] assessed the efficacy and
safety of ivermectin 10 mg/g cream (ivermectin
cream) once daily versus vehicle applied once
daily to their entire face for 12 weeks in patients
with PPR. Ivermectin cream was significantly
superior to vehicle in reducing the
inflammatory lesions count from baseline; this
was observed as early as Week 2 [59]. The
median reduction from baseline in
inflammatory lesion counts for both studies
with ivermectin cream was 76.0% and 75.0%,
respectively, versus 50.0% in both vehicle
groups at Week 12 (P\0.001) [59]. At
Week 12, for Studies 1 and 2, 38.4% and
40.1% of patients treated with ivermectin
10 mg/g cream, respectively, had an
Investigator’s Global Assessment (IGA) of 0 or
1 (‘clear’ or ‘almost clear’), compared with
11.6% and 18.8% of those treated with vehicle
(both P\0.001) [59]. Ivermectin cream was well
tolerated and shown to be safe over the 12-week
study period, with a lower incidence of
treatment-related dermatological adverse
events (AEs) compared with vehicle (3.5% and
1.5% versus 6.9% and 5.7%, respectively) [59].
Based on the results observed in the vehicle
group in terms of reduction in inflammatory
lesion counts, the vehicle formulation of
ivermectin cream is also thought to play a role
in reducing inflammation in rosacea, although
further studies will be needed to support this
initial observation.
As an extension to these studies, two 40-week
investigator-blinded active controlled studies
were conducted with ivermectin cream once
daily and with azelaic acid 150 mg/g gel twice
daily (azelaic acid gel) [69]. Azelaic acid is also
known to act as an anti-inflammatory agent by
inhibiting ROS formation and release by
neutrophils [70]; and by reducing signaling via
the CD36/NADPH oxidase, MAPK/NFjB, and
KLK5/cathelicidin pathways, which indirectly
inhibits production of pro-inflammatory
cytokines [70–72]. Investigation of the long-term
safety of ivermectin cream compared with azelaic
acid gel revealed that ivermectin cream was safe
and well tolerated in this long-term comparator
study, with a lower incidence of treatment-related
dermatological AEs compared with azelaic acid
gel [69].
Metronidazole is also indicated for use
against inflammatory lesions of rosacea and is
known to target inflammation by decreasing
ROS levels through scavenging and
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inactivation, and inhibiting production of these
free oxygen radicals, which helps to protect the
skin from damage [73]. An investigator-blinded,
randomized, parallel-group study was
conducted to demonstrate the superiority of
ivermectin cream versus metronidazole
7.5 mg/g cream twice daily (metronidazole
cream) in patients with moderate or severe
inflammatory lesions of rosacea [68].
Ivermectin cream was found to be significantly
superior to metronidazole cream in reducing
inflammatory lesion counts from 3 weeks of
treatment initiation, with a good safety profile
[68]. Following this superiority study, patients
who were initially successfully treated with
ivermectin cream or metronidazole cream (i.e.,
‘clear’ or ‘almost clear’, IGA 0 or 1) were
enrolled to an extension study, in which the
study treatment was discontinued [74]. Length
of remission was monitored and patients were
only re-treated with the initial agent if they
presented with an IGA C2 during the 36-week
extension [74]. Overall, ivermectin cream
significantly extended remission of disease
compared with initial treatment with
metronidazole cream following treatment
Fig. 2 Proposed targets of ivermectin in the inﬂammatory
pathways in rosacea. Overview of molecular and cellular
targets of ivermectin (green triangle). Ivermectin is an
anti-parasitic, which is known to target Demodex mites,
which can be found at increased levels in patients with
rosacea. Ivermectin also inhibits multiple pro-inﬂammatory
cytokines, including IL-1b, IL-6, and TNF-a; and
inﬂammatory mediators such as NO, COX2, and PGE2.
COX2 cyclooxygenase-2, IL interleukin, KLK kallikreins,
MMP matrix metalloproteinases, NO nitric oxide, PGE2
prostaglandin E2, ROS reactive oxygen species, TLR2
toll-like receptor 2, TNF tumor necrosis factor, VEGF
vascular endothelial growth factor. Adapted from Casas
et al. [19], Yamasaki et al. [29, 30], Muto et al. [32], and
Zhang et al. [66, 67]
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cessation [74]. Evidence from clinical studies
demonstrates that ivermectin cream rapidly and
effectively reduces inflammatory lesions, even
in severe cases of rosacea.
Doxycycline
Despite rosacea being an inflammatory
disease, the use of antibiotics is a common
practice in dermatology [75]; and oral
antibiotics have been used in the treatment
of rosacea since the 1950 s [76]. Due to the
chronicity of rosacea, antibiotic use is often
over the long term, which can result in side
effects such as candidal vulvovaginitis,
gastrointestinal (GI) distress, dose-dependent
photosensitivity, lupus-like syndrome, vertigo,
hypersensitivity, and blue dyspigmentation
[76–79].
Tetracyclines are a class of antibiotics that
includes the second-generation derivatives
doxycycline, minocycline, and lymecycline
[76, 80–83], which have broad-spectrum
activity [76]. Antibiotics were first widely
prescribed by dermatologists in the 1950s,
when it was discovered that they were
effective in the treatment of acne [82].
Doxycycline and minocycline were approved
in 1966 and 1973, respectively [76]; and have an
improved bioavailability, longer elimination
half-life and can be administered with food,
which minimizes GI side effects [82].
Tetracyclines have been demonstrated to:
downregulate the production of the
pro-inflammatory cytokines IL-1 and TNF-a;
inhibit neutrophil chemotaxis; inhibit the
production of NO, ROS, and MMPs [76, 80];
increase epidermal hydration (following
TEWL), and reduce erythema on the cheeks
and centro-facial regions (determined by
erythema index and melanin index of the
skin) [44].
Although antibiotics have been a mainstay
treatment for the inflammatory lesions of
rosacea, there is increasing concern regarding
the development of antibiotic resistance with
prolonged use of these agents, which could
potentially result in adverse global health
consequences [76]. There has been a call to
minimize or discontinue routine and regular
use of antibiotics in the treatment of skin
diseases such as acne and rosacea [84].
Tetracyclines are the most commonly
prescribed type of oral antibiotic, with
doxycycline accounting for approximately
one-third of prescriptions, and over the past
three decades, bacterial resistance to
tetracycline has increased [75]. Traditional
doses of immediate-release doxycycline
(C 50 mg) can exert selection pressure,
increasing the risk of bacterial resistance [80].
They can also alter the balance of commensal
microflora, which can predispose patients to
side effects such as vaginal candidiasis [80].
Doxycycline 50–200 mg is commonly
prescribed off-label for rosacea based on its
anti-inflammatory properties [76, 85], which
unnecessarily exposes patients to antibiotics
[76, 84]. A prospective, placebo-controlled,
randomized, double-blind trial in 29 healthy
volunteers demonstrated that daily
administration of oral doxycycline 100 mg was
associated with a significant increase in
doxycycline-resistant nasopharyngeal flora
measured at Days 7 and 14, which continued
for more than 2 weeks after cessation of therapy
[86]. Daily treatment with doxycycline 100 mg
has also been shown to induce microbial
resistance as early as 7 days after the start of
treatment [86].
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Doxycycline 40 mg Modified-Release
(Anti-Inflammatory Dose)
In 2006, doxycycline 40 mg modified-release
became the first FDA-approved oral treatment
for PPR and the only FDA-approved tetracycline
indicated for long-term use for up to 9 months
[87]. The once-daily capsule formulation of
doxycycline monohydrate contains 30 mg
immediate-release and 10 mg delayed-release
doxycycline [88].
Doxycycline 40 mg modified-release achieves
plasma concentrations of doxycycline
(*500 ng/mL) that fall below the minimum
inhibitory concentration (MIC) of doxycycline-
susceptible bacteria (1000 ng/mL) in comparison
to doxycycline 50 mg (1200 ng/mL), while
delivering a strong anti-inflammatory response
(Fig. 3) [80]. Consequently, the modified-release
formulation does not induce antimicrobial
resistance or affect commensal microflora [80].
Preclinical studies using doxycycline 40 mg
modified-release demonstrated its ability to
inhibit generation of active cathelicidin
peptides via the direct inhibition of MMP
activity (and repression of MMP gene
expression) and indirect inhibition of KLK5
serine protease activity (Fig. 4) [36].
Doxycycline 40 mg modified-release has also
been shown to have anti-angiogenic effects,
through its inhibition of MMPs, which are
essential for the coordinated degradation of
matrix during angiogenesis [89]. Inhibition of
MMPs indirectly inhibits vascular endothelial
growth factor (VEGF)-induced angiogenesis
(evidence suggests that neutrophils express
VEGF, VEGF receptor [VEGFR]-1, and VEGFR-2
in rosacea, and VEGF is known to be a potent
Fig. 3 Doxycycline 40 mg modiﬁed-release plasma
concentration remains below the antimicrobial threshold
[80]. Graph showing plasma concentration of doxycycline
50 mg once daily (gray) and doxycycline 40 mg/g
modiﬁed-release (orange) compared with the antimicrobial
threshold (red dotted line)
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stimulator of angiogenesis) [80, 90]. In addition,
doxycycline 40 mg modified-release is a more
potent inhibitor of MMPs than minocycline or
tetracycline, acting as a non-competitive
inhibitor of these enzymes [80].
A recent study indicates that patients with
rosacea may be at a higher risk of developing
cardiovascular disease (CVD) [91]. MMPs have
been shown to be influential in the pathology
of both rosacea and CVD [92], triggering an
inflammatory pathway via production of KLK5
and cathelicidin and subsequent production of
LL-37 [36]. Based on the fact that doxycycline
40 mg modified-release inhibits MMP activity,
this agent could potentially also be beneficial in
the prevention or reduction of CVD risk, as
doxycycline has previously been shown to:
defend capillary wall and connective tissue
integrity; reduce hypersensitivity to
vasodilatory stimuli; prevent leakage of
capillaries: and inhibit cytokines involved in
inflammation [92]. Furthermore, it has been
observed that sub-antimicrobial-dose
doxycycline (20 mg twice daily) lowers the
levels of the inflammatory biomarker serum
C-reactive protein (CRP), with elevated CRP
Fig. 4 Proposed targets of doxycycline 40 mg modiﬁed-
release on inﬂammatory pathways in rosacea based on
current evidence [14, 36, 76, 80, 94]. Overview of
molecular and cellular targets of doxycycline 40 mg
modiﬁed-release (orange circle). Doxycycline 40 mg
modiﬁed-release acts on several targets in the cathelicidin
pathway, including MMPs, KLKs (e.g., KLK5), and
cathelicidin. It also acts on pro-inﬂammatory cytokines,
including IL-1b, IL-8, and TNF-a; and inﬂammatory
mediators such as ROS. IL interleukin, KLK kallikreins,
MMPs matrix metalloproteinases, NO nitric oxide, PGE2
prostaglandin E2, ROS reactive oxygen species, TLR2
toll-like receptor 2, TNF tumor necrosis factor, VEGF
vascular endothelial growth factor. Adapted from Del
Rosso et al. [14], Kanada et al. [36], Di Nardo et al. [40],
Baldwin [76], Fowler [80], and Cazalis et al. [94]
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levels being a known CVD risk factor [93]. By
inhibiting the production and activity of MMPs,
doxycycline 40 mg modified-release blocks
multiple inflammatory pathways, which
inhibits the production of proteins
contributing to the pathophysiology of PPR
inflammation. This ultimately reduces the
inflammation associated with inflammatory
lesions of rosacea [36, 94].
Although doxycycline 40 mg modified-release
acts as an anti-inflammatory agent [76, 80], it
does not have antimicrobial activity [80, 95], and
does not exert selective pressure on
microorganisms or encourage the development
of bacterial resistance [76]. In a 9-month,
multicenter, randomized, double-blind,
placebo-controlled trial, subgingival samples
were collected from adult patients with
periodontitis at baseline and after 9 months of
doxycycline 40 mg modified-release once-daily
(n= 34) or placebo therapy (n= 36) [80, 96].
Treatment with either doxycycline 40 mg
modified-release or placebo did not result in the
development of antibiotic resistance, and only a
minor comparable increase in
doxycycline-resistant bacteria was observed in
both study arms after 9 months (5.09% vs.
5.38%, respectively; P= 0.965) [80, 96].
In patients with rosacea, the efficacy and
safety of doxycycline 40 mg modified-release
(anti-inflammatory dose) has been investigated
versus placebo [95] and doxycycline 100 mg
[97]. In two trials, adult patients with
inflammatory lesions (moderate to severe
disease) were randomized to receive either
doxycycline 40 mg modified-release (n = 269)
or placebo (n = 268) once daily [95]. The mean
total inflammatory lesion count of patients was
19.9 in Study 1 and 20.8 in Study 2 [95]. At
Week 16, the mean change from baseline in
inflammatory lesion counts in the active
treatment groups was -11.8 in Study 1 and
-9.5 in Study 2, compared with -5.9 and -4.3
in the placebo groups, respectively (P\0.001
for both comparisons) [95]. In addition,
doxycycline 40 mg modified-release was well
tolerated, with a similar number of AEs
experienced by patients in both groups [95]. In
a separate 16-week study, the efficacy and safety
of doxycycline 40 mg modified-release was
compared with those of doxycycline 100 mg,
showing that reduction in inflammatory lesion
counts from baseline was similar in the two
groups; at Week 16, the mean change in
inflammatory lesion counts from baseline was
-14.3 with doxycycline 40 mg modified-release
compared with -13.0 with doxycycline 100 mg
[97]. Overall, doxycycline 40 mg
modified-release was shown to have similar
efficacy to doxycycline 100 mg, with
approximately five times fewer gastrointestinal
AEs [97]. In studies with healthy volunteers
administered doxycycline 40 mg
modified-release (n = 16) or doxycycline 50 mg
(n = 16), doxycycline 40 mg modified-release
reached steady-state plasma concentrations
that remained below the MIC of common
doxycycline-susceptible microorganisms
throughout a 24-hour dosing period [80]. In
contrast, with conventional immediate-release
doxycycline 50 mg, steady-state plasma








Ivermectin and doxycycline 40 mg
modified-release have different targets in the
inflammatory pathways of rosacea, with each
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agent providing add-on effects summarized in
Table 1 and presented in Fig. 5
[36, 55, 64, 66, 80, 94]. Treatment efficacy could
be increased if these two agents were used in
combination, through a targeting of multiple
steps of different inflammatory pathways.
Doxycycline 40 mg modified-release targets
MMPs and ROS, indirectly blocking production
of inflammatory mediators [36, 80, 89]. Oral
ivermectin has been shown to inhibit T cell
activation, release of pro-inflammatory
mediators, macrophage and neutrophil
recruitment, as well as reducing levels of
Demodex mites on the skin, which prevents the
subsequent amplification of the inflammatory
response [64–66]. In addition, these agents also
act on several common targets, which further
reduce the intensity of the inflammatory
response. In a recent preclinical study, the
synergistic activity of doxycycline and
ivermectin was demonstrated to be effective in
the complete eradication of body lice [98]. The
hypothesis is that combining treatments which
act on different targets within inflammatory
pathways could provide improved results for
patients with inflammatory lesions of rosacea.
Results from combination studies provide a
rationale for the combinatorial use of agents in
the treatment of inflammatory lesions of
rosacea. In a 16-week, randomized,
Table 1 Overview of proposed molecular and cellular targets of ivermectin and doxycycline, based on current knowledge
[14, 36, 40, 55, 65–67, 76, 80, 94]
Target Agent
Ivermectin Doxycycline



















Tick marks in black indicate that an agent acts on a speciﬁc target. Tick marks in green indicate that only either ivermectin
or doxycycline acts on a speciﬁc target
COX2 cyclooxygenase-2, IL interleukin, KLKs kallikreins, MAPK mitogen-activated protein kinases, MMPs matrix
metalloproteinases, NO nitric oxide, PGE2 prostaglandin E2, ROS reactive oxygen species, TNF-a tumor necrosis factor
alpha
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double-blind, placebo-controlled study, adult
patients with inflammatory lesions of rosacea
(8–40 inflammatory lesions) and moderate to
severe erythema were randomized to oral
doxycycline 40 mg modified-release and
topical metronidazole 10 mg/g gel once daily
(Group 1) or placebo and topical metronidazole
10 mg/g gel once daily (Group 2) for 12 weeks;
double-blind administration of doxycycline
40 mg modified-release or placebo was
continued up to Week 16 [99]. Combination
therapy significantly reduced inflammatory
lesion counts from Week 4, i.e., with a faster
onset of action than metronidazole
monotherapy, and continued to Week 12
compared with metronidazole 10 mg/g gel
monotherapy [99]. Total inflammatory lesion
count at baseline was 21.3 in Group 1 and 18.7
in Group 2 [99]. From baseline to Week 4, the
mean change in inflammatory lesions count
was -9.69 in Group 1 compared with Group 2
(P = 0.008); and at Week 12 was -13.86 versus
-8.7, respectively (P = 0.002) [99].
DISCUSSION
The combination of augmented immune
responses (inflammation), neurovascular
dysregulation, and physiochemical and
structural changes contributes to the
Fig. 5 Proposed complementary targets of ivermectin and
doxycycline 40 mg modiﬁed-release in the inﬂammatory
pathways in rosacea based on current evidence. IL
interleukin, KLK kallikreins, MMPs matrix
metalloproteinases, NO nitric oxide, PGE2 prostaglandin
E2, ROS reactive oxygen species, TLR2 toll-like receptor 2,
TNF tumor necrosis factor, VEGF vascular endothelial
growth factor. Adapted from Del Rosso et al. [14], Casas
et al. [19], Yamasaki et al. [29, 30], Muto et al. [32],
Kanada et al. [36], Di Nardo et al. [40], Zhang et al.
[66, 67], Baldwin [76], Fowler [80], Cazalis et al. [94]
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pathogenesis of rosacea [12, 25, 26]. Increased
expression of specific proteins such as MMPs,
KLK5, cathelicidin, and LL-37, as well as
cytokines such as IL-1, TNF-a, and IFN-c
contribute to a heightened and constitutively
active inflammatory response, leading to the
development of inflammatory lesions
[29, 35–37]. Oral ivermectin has been shown
to inhibit the activation of T cells (Ventre et al.,
submitted) and the production of
pro-inflammatory cytokines [66], and to
reduce levels of Demodex mites on the skin
[41, 55, 64]. Doxycycline 40 mg
modified-release, a tetracycline derivative with
anti-inflammatory and sub-antimicrobial
activity, has been shown to inhibit MMPs and
suppress the production of KLK5, the
cathelicidin peptide LL-37, as well as inhibit
the production of certain pro-inflammatory
cytokines [36, 94]. Both ivermectin 10 mg/g
cream and doxycycline 40 mg modified-release
have been shown to be clinically effective in
reducing the number of inflammatory lesions in
patients with PPR; in addition, both agents have
a good safety profile [59, 68, 69, 95, 97].
Based on the initial evidence of the efficacy
of combinatorial therapies, both in rosacea [99]
and in the treatment of other dermatological
diseases such as acne [27], the combination of
topical ivermectin 10 mg/g cream with oral
doxycycline 40 mg modified-release could
provide an intensive initial regimen, especially
for those patients with more involved disease or
when a fast onset of action is required. Onset of
treatment effect can be seen as early as 2 weeks
after treatment initiation with ivermectin
10 mg/g cream monotherapy [59] and 3 weeks
with doxycycline 40 mg modified-release
monotherapy [95]; onset of action could
potentially be faster, with a potentially larger
reduction in inflammatory lesions, if these
agents were to be used in combination.
SUMMARY AND CONCLUSIONS
Given the chronic nature of rosacea, the need
for continuous therapy often leads to reduced
adherence in patients with this disease [76]. A
fast onset of action means that patients would
see the benefits of treatment immediately, and
be more likely to continue treatment as
prescribed. Clinical evidence seems to support
that a combination of these two agents as an
intensive initial treatment would be effective in
patients with severe disease, i.e., disease with a
high inflammatory component, or when a fast
onset of results is sought. Both ivermectin and
doxycycline 40 mg modified-release act on
inflammatory pathways, which results in
modulation of the production of downstream
inflammatory mediators. This could potentially
also help patients see results early on in their
treatment, which in turn could improve
long-term adherence.
Further research is needed to correlate
clinical manifestations in patients with
rosacea with predominance of certain
inflammatory cascades. This will allow
clinicians to identify which patients will most
benefit from monotherapy versus combination
therapy and enable treatments to be tailored to
individual patients, depending on their
symptoms. The use of combination therapies
in rosacea has yet to be thoroughly evaluated
and validated, and clinical studies that
investigate the efficacy of combination
regimens are needed. Availability of such data
would provide a clear message regarding
optimal, individualized treatment options.
However, current evidence suggests that the
combinatorial treatment of topical ivermectin
10 mg/g cream and oral doxycycline 40 mg
modified-release should be used as the first-line
treatment for inflammatory lesions of rosacea
for optimal efficacy.
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